TheStreet’s Feuerstein to Sarepta (SRPT) CEO: Shut Up About Ebola

TheStreet’s Adam Feuerstein sees Sarepta Therapeutics (SRPT) jump into the media blitz surrounding the Ebola outbreak as an opportunistic way to publicize itself. In an article about the firm’s public outreach to the U.S. government about its AVI-7537, an experimental injectible Ebola treatment that has had survival rates of up to 80% against the deadly […] View the full post at: TheStreet’s Feuerstein to Sarepta (SRPT) CEO: Shut Up About Ebola Related posts: Satellite Hedge Fund to Shut Down After Client Withdrawals
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.